Sam Tetlow, MBA
Chairman of the Board
Sam has a strong track record as a catalyst for life science company growth over the last 15 years and delivering returns in both management and investor roles. In addition to BioFluidica, Sam is CEO of EpiCypher, a company located in Chapel Hill, N.C. that sells products and services in the area of epigenetics. Previously, Sam was with ILS where he led organic growth in the commercial sectors and launched ILS Genomics. Sam was General Manager and led the Company from inception through its first full year of operations; ILS Genomics continues to grow today. During this time, Sam was a lead director with Immunologix, a humanized therapeutic antibody spinout that was launched, built and sold for a 10x return for investors within a 24-month period. Prior to that, Sam was a full time Partner with Research Triangle Ventures, where he led the full cycle of life science investing. Sam has a Bachelor of Science degree from Worcester Polytechnic Institute, honors, and a MBA from UNC Kenan-Flagler Business School, also with.
Michael is an entrepreneurial healthcare and life sciences professional with 20 years of experience leading innovative business initiatives across the pharmaceutical, biotechnology and clinical laboratory industries by driving strategic vision, business partnerships and value-added product development. He has made significant impacts on the development and commercialization of over a dozen products in drug discovery & development, as well as several companion diagnostics and contributed to the production of a biopharmaceutical. He is currently the CEO of Inivata Limited, as well as the Founder and President of Personalized Medicine Partners LLC. Prior he was the CEO of On-Q-ity, and the Director of Business Development at GlaxoSmithKline.
Rolf Muller, Ph.D.
Chief Executive Officer
Rolf Muller is a biotechnology leader combining science and business knowledge to build and grow successful technology companies that further healthcare and the field of personalized medicine. He has structured and guided highly efficient multi-disciplinary research and commercial teams through funding, to product development, and successful product launch into global markets. Prior to joining BioFluidica he was the Founder and President of Biomatrica, which he developed from an idea to be a global leader in biopreservation technologies for diagnostic and health care companies. Over the last 16 years he has been involved in analyzing markets and developing strategies to position biotechnologies to maximize value. He has interacted with most of the major pharma and biotechnology companies to obtain funded development contracts, joint projects, and partnerships. In addition to raising successfully capital from investors he also raised non-dilutive capital from CDC, NCI, NIH, DARPA, In-Q-Tel and DOD. He obtained his Ph.D. in biochemistry from the Pasteur Institute in Paris France.
Steven A. Soper, Ph.D.
Cofounder and Chief Technology Officer
Dr. Steven A. Soper founded Biofluidica in order to develop new technologies to be used in the medical diagnostic, pathogen detection, and personalized medicine spaces. He is a worldwide recognized pioneer in the development of diagnostic platforms with over 12 years of experiences in the CTC research area along with being the author of five patents currently licensed by BioFluidica. He has over 310 peer-reviewed publications with an h-index of 56. In addition, he has generated over $60M in competitive research funding over his career with most of this funding focused on developing new technologies for in vitro diagnostics. Dr. Soper is currently a Professor in Biomedical Engineering and Chemistry at UNC-CH. He is also Director of a new Center on the UNC-CH campus; Center for BioModular Multi-scale Systems for Precision Medicine, which is focused on developing new tools for the molecular analysis of circulating biomarkers.